SARS-CoV-2 DNA Vaccine INO-4800 Induces Durable Immune Responses Capable of Being Boosted in a Phase 1 Open-Label Trial

Kraynyak, KA; Blackwood, E; Agnes, J; Tebas, P; Giffear, M; Amante, D; Reuschel, EL; Purwar, M; Christensen-Quick, A; Liu, NM; Andrade, VM; Diehl, MC; Wani, S; Lupicka, M; Sylvester, A; Morrow, MP; Pezzoli, P; McMullan, T; Kulkarni, AJ; Zaidi, FI; Frase, D; Liaw, K; Smith, TRF; Ramos, SJ; Ervin, J; Adams, M; Lee, J; Dallas, M; Brown, AS; Shea, JE; Kim, JJ; Weiner, DB; Broderick, KE; Humeau, LM; Boyer, JD; Mammen, MP

Humeau, LM (通讯作者)，Inovio Pharmaceut, 660 W Germantown Pike,Suite 1110, Plymouth Meeting, PA 19462 USA.

JOURNAL OF INFECTIOUS DISEASES, 2022; 225 (11): 1923

Abstract

Background Additional severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines that are safe and effective as primary vaccines and booste......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索